By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today announced it is further extending its cash tender offer for Orchid Cellmark as it continues to provide answers to questions about the deal to the US Federal Trade Commission.

The $85.4 million proposed deal, announced in April, has been extended to 5 p.m. EDT, Nov. 14. It was previously extended to Nov. 4, and now has been extended eight times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.